Yes, Arizona’s Alternative Business Structure (ABS) program is actively reshaping how mass tort law firms are built, funded, and operated. In 2020, Arizona became the first U.S. state to eliminate its version of ABA Model Rule 5.4, the rule that for decades barred nonlawyers from owning or sharing in the profits of a law firm. By adding Supreme Court Rules 31 and 31.1(c) and launching its licensing program in 2021, the state opened the door for investors, technologists, and other professionals to hold ownership stakes in firms—provided an Arizona-licensed lawyer still handles all actual legal work. That single regulatory shift has become a magnet for capital flowing into personal injury and mass tort litigation.
The clearest example is Justpoint Law, LLP, which in July 2025 received Arizona Supreme Court approval to operate as what it describes as the first AI-native U.S. mass tort firm. Backed by $105 million in combined funding, Justpoint uses proprietary technology to sift through medical records, FDA adverse-event reports, and scientific literature to identify dangerous products and the people they harm. The firm represents a new template: outside money and software engineering fused directly into a litigation practice, something that would be flatly illegal in 48 other states. This article explains how the Arizona framework works, why mass tort and personal injury firms are clustering around it, and what the model means for plaintiffs, investors, and the broader legal market—including the friction it is already generating with neighboring states and regulators.
Table of Contents
- What Is Arizona’s ABS Program and Why Does It Fuel a New Mass Tort Firm Model?
- How Private Equity and Litigation Finance Are Reshaping Tort Firms Through ABS
- Justpoint Law and the First AI-Native Mass Tort Firm
- ABS Firms Versus Traditional Mass Tort Firms—The Tradeoffs
- The Limits, Risks, and Neighboring-State Resistance
- What ABS Means for Plaintiffs Considering a Mass Tort Claim
- Where the Numbers Stand Today
What Is Arizona’s ABS Program and Why Does It Fuel a New Mass Tort Firm Model?
An Alternative Business Structure is, in plain terms, a law firm that includes nonlawyer owners. Those owners can be private equity investors, technology companies, or other professionals who hold an economic interest or decision-making authority in the firm. The critical limitation, spelled out by the Arizona courts and firms like Holland & Knight that advise applicants, is that nonlawyer owners may not give legal advice or practice law. Only an Arizona-licensed attorney can do that. The ownership reform changes who profits and who governs—not who litigates. Why does this fuel a new mass tort model specifically? Mass tort litigation is capital-intensive.
Identifying claimants, screening medical histories, advancing case costs, and waiting years for resolution all require money up front. Under traditional Rule 5.4, a firm could only raise that money through lawyer partners or expensive litigation loans. The ABS structure lets outside investors take equity directly, aligning their returns with case outcomes. As of March 2026, 150 ABS entities were licensed in Arizona, and the state updated its applicant criteria that same month in response to industry feedback. Compare this to the conventional contingency-fee firm in a state like California or New York: the firm fronts costs from its own balance sheet or borrows against future fees, and a software vendor that builds case-screening tools can only ever be a paid contractor, never a partner. In Arizona, that vendor can own a slice of the firm. That difference is precisely what makes the state attractive to data-driven mass tort operations.
How Private Equity and Litigation Finance Are Reshaping Tort Firms Through ABS
The money trail tells the story. Of the 76 ABS applications approved since 2020, at least 15 involve private equity or litigation finance, and reporting from Bloomberg Law suggests as much as 40% of ABS-approved businesses are backed by private equity or hedge funds. About one-third of ABS firms concentrate on personal injury and mass tort litigation—the categories that promise the largest aggregate recoveries and the most predictable, if delayed, returns. One Arizona ABS firm reportedly severed its back office for a $125 million investment, a figure that signals how seriously institutional capital is treating the opportunity. The new model is essentially a national tort practice headquartered, for licensing purposes, in Phoenix.
An investor-backed firm can use Arizona as its regulatory home base while pursuing federal multidistrict litigation that draws plaintiffs from across the country. This is efficient, but it carries a real limitation and a warning: the influx of profit-seeking capital raises legitimate questions about whether case selection and settlement decisions will be driven by client interest or investor return. Critics worry that when a hedge fund holds equity, the pressure to resolve cases quickly—or to chase the highest-volume tort regardless of individual merit—can quietly override the lawyer’s independent professional judgment that Rule 5.4 was designed to protect. The Arizona Supreme Court’s policy body has not ignored this. It updated the rules to crack down on firms using the program primarily to generate leads for lawyers in other states, an early sign that regulators are watching for abuse rather than letting the market run unchecked.
Justpoint Law and the First AI-Native Mass Tort Firm
Justpoint Law, LLP is the most concrete illustration of what the ABS framework makes possible. The firm received Arizona Supreme court approval in July 2025 and publicly announced its launch on February 10, 2026, billing itself as the first AI-native U.S. mass tort firm. Its technology analyzes billions of data points—medical records, FDA adverse-event databases, and published scientific literature—to flag products that may be causing harm before traditional intake methods would surface a pattern.
The funding behind it is substantial: $105 million in total, consisting of a $45 million Series A plus a $50 million line of credit led by SignalFire. The parent company, Justpoint, Inc., was founded in 2018 and says it has helped more than 10,000 plaintiffs through earlier firm partnerships. CEO and co-founder Victor Bornstein framed the ambition directly: “We’ve essentially created a new model for representing victims of harmful FDA-regulated products that allows for significantly faster justice administration.” The example is instructive because it shows the two halves of the ABS bargain working together. The venture-style capital pays for the engineering and the case costs; the Arizona license lets that capital sit inside the firm rather than beside it. Strip out either piece and the model collapses back into a conventional, slower-moving practice.
ABS Firms Versus Traditional Mass Tort Firms—The Tradeoffs
For a plaintiff weighing representation, the differences between an ABS firm and a traditional contingency shop are real but not always obvious. An ABS firm backed by tens of millions in capital can theoretically afford deeper investigation, faster medical review, and the patience to litigate against well-funded corporate defendants without folding under cost pressure. Technology-driven intake may also catch viable claims that a conventional firm, working from advertising and word-of-mouth, would never identify. Those are genuine advantages. The tradeoff is the introduction of a profit motive that sits one layer removed from the courtroom.
In a traditional firm, the partners who decide whether to accept a settlement are the same lawyers bound by duties to the client. In an ABS, investors who are not bound by those professional duties hold an economic stake in the outcome. Arizona’s rules require that the licensed lawyer retain control over legal decisions, but the structural tension is unavoidable: the people funding the firm want returns, and returns in mass tort come from volume and speed. A useful comparison is the litigation-funding arrangements that already exist nationwide, where outside financiers bankroll cases in exchange for a cut of recoveries. ABS goes a step further by putting those financiers inside the firm’s ownership rather than in a separate contract. That deeper integration can mean better alignment and faster execution, or it can mean investor priorities seeping further into legal strategy than a one-off funding deal ever could.
The Limits, Risks, and Neighboring-State Resistance
The ABS model is geographically fragile. Arizona stands alone among states in fully eliminating Rule 5.4, which means an ABS firm operating nationally is constantly working at the edges of other states’ ethics rules. A nonlawyer-owned firm licensed in Phoenix cannot simply set up shop in Texas or Florida and practice the same way; it must navigate each jurisdiction’s restrictions on fee-sharing and unauthorized practice. The Arizona State Law Journal has documented the “neighboring resistance” the program faces, and that friction is a structural ceiling on how far the model can expand under current law. There is also a warning embedded in the regulatory record itself.
The Arizona Supreme Court’s decision to tighten rules against firms using ABS licenses mainly to generate leads for out-of-state lawyers shows that the program’s openness invites attempts to game it. A firm that is technically Arizona-licensed but functionally a marketing funnel for practitioners elsewhere undermines the consumer-protection rationale behind the reform. Plaintiffs should understand that an ABS badge does not, by itself, guarantee that their case will be handled within Arizona or by the people the firm’s branding implies. Finally, the model is young. The licensing program only began in 2021, the criteria were revised as recently as March 2026, and firms like Justpoint have years of litigation ahead before anyone can judge whether AI-native, investor-backed mass tort practice actually delivers better outcomes for clients—or simply better returns for backers.
What ABS Means for Plaintiffs Considering a Mass Tort Claim
For someone deciding whether to join a mass tort over a defective drug or medical device, the practical takeaway is to ask how a firm is structured and funded. An ABS firm may have more resources and faster screening, but a claimant should confirm that an Arizona-licensed attorney is responsible for their case and ask plainly how settlement decisions get made. Justpoint’s pitch—using FDA adverse-event data to identify harmed plaintiffs early—can be genuinely valuable, but the same data-driven approach that finds strong cases can also sweep in marginal ones if volume is the goal.
A concrete example of the stakes: in mass tort programs involving thousands of plaintiffs, individual settlement allocations are often determined by points-based matrices rather than individual trials. The quality of the firm advancing your claim—its willingness to document your specific injury thoroughly rather than process you as one more file—directly affects your recovery. Capital and software help, but they do not replace attentive lawyering.
Where the Numbers Stand Today
As of March 2026, Arizona had licensed 150 ABS entities, up from a standing start in 2021. Roughly one-third focus on personal injury and mass tort work, and of the 76 applications approved since 2020, at least 15 carry private equity or litigation-finance backing.
Justpoint Law’s $105 million in funding—a $45 million Series A and a $50 million credit line from SignalFire—sits among the larger publicly disclosed commitments, while a separate ABS firm’s reported $125 million back-office investment shows the figures climbing higher still. These are the concrete data points defining the program at this moment.